Xencor, Inc. (NASDAQ:XNCR) Stock Holdings Raised by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System grew its stake in Xencor, Inc. (NASDAQ:XNCR) by 12.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,567 shares of the biopharmaceutical company’s stock after purchasing an additional 2,686 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Xencor were worth $542,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. GAMMA Investing LLC raised its stake in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV raised its position in shares of Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 813 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in Xencor by 8.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 949 shares during the period. Point72 DIFC Ltd increased its stake in Xencor by 10.9% during the third quarter. Point72 DIFC Ltd now owns 13,511 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 1,333 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,337 shares during the last quarter.

Xencor Stock Down 1.9 %

XNCR opened at $12.95 on Tuesday. The stock’s 50 day moving average price is $16.22 and its 200 day moving average price is $20.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The stock has a market cap of $912.48 million, a P/E ratio of -4.05 and a beta of 0.74. Xencor, Inc. has a 12 month low of $12.54 and a 12 month high of $27.24.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on XNCR. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $30.00 in a report on Monday, December 2nd. Wells Fargo & Company lowered their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Finally, StockNews.com downgraded Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and a consensus target price of $34.38.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.